2022年10月18日

明尼阿波利斯，2022年10月18日/PRNewswire/——Bio-Techne公司(納斯達克代碼:TECH)今天宣布，Bio-Techne品牌Exosome Diagnostics報告了一項基於新型外泌體的平台的概念驗證研究的結果，該平台可以監測宇航員在太空中的關鍵生物變化。這篇同行評議的論文發表在《自然》雜誌的npj微重力雜誌上。從太空微重力環境返回的宇航員經常遭受視力障礙、顱內壓和其他不太清楚的健康問題。這些症狀統稱為航天相關神經眼綜合征(SANS)。隨著宇航員被派往更長時間的任務，以及商業航天飛行允許非宇航員達到微重力，對SANS的生物機製研究和診斷該綜合征的可靠技術的需求越來越大。外泌體是由細胞釋放的含有蛋白質和RNA等分子物質的粒子，是細胞間自然通訊係統的一部分。它們的分子內容可以揭示有關健康和疾病的重要信息。外泌體存在於血液、腦脊液和尿液等體液中。它們可以通過非侵入性液體活檢方法獲得，這使它們成為監測宇航員在太空中旅行動態變化的挑戰的理想解決方案。在《npj微重力》雜誌上報道的這項研究中，來自外泌體診斷、貝勒醫學院和NASA承包商KBR的科學家們證明，外泌體可以從國際空間站收集的生物液體中提取，並儲存起來用於未來的分析，它們的分子內容可以揭示有關關鍵途徑的轉錄組範圍的信息，這可能有助於闡明SANS。 "Exosome Diagnostics has spent years developing and optimizing a platform for whole-transcriptome profiling based on exosome isolation and analysis. Our platform is designed for noninvasive monitoring of health and disease with a depth and breadth that are not possible using other approaches," said Johan Skog, Chief Scientific Officer and Vice President at Exosome Diagnostics. "We have worked closely with NASA to ensure that this technology will be applicable for space travelers, who are exposed to microgravity, different air composition, and radiation. This demonstration clearly shows that exosome-based analysis is a feasible and powerful approach for longitudinal monitoring of the dynamic biological changes that may arise from those conditions." "We are excited about the potential for our technology to keep astronauts healthier, and also believe that our multi-analyte exosome analysis platform will enable a wide range of precision medicine applications here on Earth," said Kim Kelderman, President of the Diagnostics and Genomics Segment at Bio-Techne. "With an extremely robust and reproducible workflow, our approach to exosome analysis is useful for any research group interested in pathway profiling, patient stratification, and biomarker development." Paper cited: Chakrabortty, S.K., Khodor, Y.L., Kitchen, R.R. et al. Exosome based analysis for Space Associated Neuro-Ocular Syndrome and health risks in space exploration. npj Microgravity 8, 40 (2022). https://doi.org/10.1038/s41526-022-00225-4